Treatment
Pirfenidone clinical trials
We’re tracking 16 recruiting studies that include Pirfenidone, each written for real people, not researchers, below.
Recruiting studies
- NCT06484153RecruitingPhase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Wuhan, HubeiAges 18–75 - NCT07388680RecruitingPhase 2/Phase 3
Pirfenidone for radiation lung injury with or without immune pneumonia
This trial tests if pirfenidone capsules can help treat lung damage caused by radiation therapy, with or without immune-related pneumonia. It may be suitable for people with mild to moderate lung function impairment who have recently developed radiation lung injury.
Hefei, AnhuiAges 18–75 - NCT06253117RecruitingPhase 2
Testing pirfenidone to prevent repeat pancreatitis attacks
This trial tests if pirfenidone, an anti-scarring drug, can reduce the number of repeat episodes of acute pancreatitis. You may be eligible if you've had two or more pancreatitis attacks at least three months apart and are not having an active attack right now.
Birmingham, AlabamaAges 18–85 - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT05075161RecruitingPhase 3
Pirfenidone to help prevent lung scarring in ARDS
This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.
Milan, MIAges 18 years+ - NCT05288179RecruitingPhase 3
Pirfenidone capsules for silicosis or coal dust lung disease
This Phase 3 trial tests whether pirfenidone slows or improves lung damage in people with silicosis or coal worker’s pneumoconiosis. It looks at both effectiveness and side effects, and uses lung function tests and lung scans to track changes over time.
BeijingAges 18–70 - NCT05350371RecruitingPhase 1/Phase 2
Testing pirfenidone to treat severe acute pancreatitis
This early-stage hospital study tests whether pirfenidone is safe and tolerable for people with acute pancreatitis that may become severe. It may help by reducing the risk of complications, while researchers carefully track side effects.
Birmingham, AlabamaAges 18–85 - NCT06928272RecruitingPhase 3
Long COVID drug study for adults 18 to 65
This study tests whether a commonly used drug (repurposed) can help improve Long COVID symptoms like fatigue, breathing problems, or brain fog. It is for adults 18 to 65 who had COVID-19 in the past 4 years and still have symptoms after 3 months.
San Diego, CaliforniaAges 18–65 - NCT07229716RecruitingPhase 1
Drug interaction study in healthy volunteers
This trial studies how a new drug (HRS-9813) interacts with two existing lung fibrosis drugs (pirfenidone and nintedanib) in healthy adults. The results will help doctors understand how to combine these medicines safely.
Xi’an, ShanxiAges 18–45 - NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT04467723RecruitingPhase 1/Phase 2
Atezolizumab plus pirfenidone for advanced lung cancer
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
Fairway, KansasAges 18 years+ - NCT05842681Recruiting
Azithromycin for early worsening of idiopathic pulmonary fibrosis
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
AsyutAges 18–80 - NCT07082842RecruitingPhase 3
Testing HEC585 tablets for idiopathic pulmonary fibrosis
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
Beijing, Beijing MunicipalityAges 40–80 - NCT03109288RecruitingPhase 1/Phase 2
Biomarker-guided combination treatment for residual multiple sclerosis activity
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Bethesda, MarylandAges 18–120 - NCT07454291RecruitingPhase 1
How taladegib works in healthy volunteers
This trial is for healthy volunteers to see how the study drug taladegib (ENV-101) interacts with other medicines in the body. It will help researchers understand how the drug is absorbed and processed, which is important for future studies in patients.
Brisbane, QueenslandAges 26–65
What Pirfenidone is being studied for
Conditions with recruiting Pirfenidone studies.
Common questions
- Are there clinical trials studying Pirfenidone?
- Yes. Clin2 currently lists 16 recruiting studies that include Pirfenidone, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pirfenidone trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pirfenidone an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pirfenidone or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.